inVentiv Health Names President for Europe and Executive Vice President for Asia to Lead Management of Growing Business
Dan Feldman Takes Reins of inVentiv Health Europe While Stephen J. Walter Joins to Lead ASEAN Countries, China and Korea
BURLINGTON, MASS., – September 26, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today the creation of two new positions to lead its growing business in Europe and Asia.
Dan Feldman, who established and led inVentiv’s very successful operation in Japan, will take on the new position of President of inVentiv Health Europe. The position will oversee the growth of business across all inVentiv Health segments – clinical research, commercialization and consulting – and will lead development of inVentiv’s unique approach to convergent services.
“In only two years, Dan established inVentiv’s outsourced sales force in Japan and grew it to become the second largest such business in the country, before moving on to establish our clinical and consulting services there,” said Paul Meister, CEO of inVentiv Health. “Dan will now be able to help our Japanese clients expand in Europe, as well as assist with our growing roster of European clients requiring services that accelerate delivery of therapies to market.”
Feldman will lead regional business development, promote inVentiv’s “Done as One” approach to convergent services and assure the continued growth of inVentiv’s European footprint.
Stephen J. Walter will join the company as Executive Vice President for Asia. Walter formerly served as Managing Director for Merck Sharpe & Dhome in Vietnam and Cambodia. Previously, he worked as General Manager and Vice President of Consulting and Services for IMS Health, based in Singapore. For Bristol-Myers Squibb, he helped launch Entecavir in the Asia Pacific region and then served as Regional Director of Business Development.
In his new role, Walter will oversee growth and management of all inVentiv Health business throughout the region, including the expansion of inVentiv’s clinical research capabilities in China.
“We are fortunate to have found someone who combines a broad knowledge of the entire Asian market with a deep understanding of what biopharmaceutical companies need in developing drugs and shepherding them through commercialization,” Meister said.
Walter, who will be based in Shanghai, will oversee inVentiv operations in the ASEAN nations, Australia and New Zealand, in addition to China and Korea. He will also assume responsibility for Japan at the end of this year, when he takes the reins from Feldman.
Walter, who won a post-graduate fellowship from the Australian Board of Trade for work in Vietnam, holds an MBA from the University of New South Wales in Sydney and a Bachelor of Science degree in microbiology and genetics from the University of Melbourne.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.